Sunitinib and other targeted therapies for renal cell carcinoma

被引：40
作者：
Powles, T. [1 ]
Chowdhury, S. [3 ]
Jones, R. [2 ]
Mantle, M. [1 ]
Nathan, P. [5 ]
Bex, A. [6 ]
Lim, L. [1 ]
Hutson, T. [4 ]
机构：
[1] St Bartholomews Hosp, Dept Med Oncol, Barts & London NHS trust, London, England
[2] Beatson Hosp Glasgow, Dept Med Oncol, Glasgow, Lanark, Scotland
[3] Guys & St Thomas Hosp, Dept Med Oncol, London SE1 9RT, England
[4] Baylor Univ, Med Ctr, Dept Med Oncol, Dallas, TX USA
[5] Mt Vernon Hosp, Dept Med Oncol, London, England
[6] Natl Canc Inst, Dept Med Oncol, Amsterdam, Netherlands
来源：
BRITISH JOURNAL OF CANCER | 2011年 / 104卷 / 05期
关键词：
renal cancer; sunitinib; mTOR; VEGF; PHASE-II TRIAL; INTERFERON-ALPHA; DOUBLE-BLIND; EFFICACY; BEVACIZUMAB; INHIBITION; SORAFENIB; GROWTH; EVEROLIMUS; RESISTANCE;
D O I：
10.1038/sj.bjc.6606061
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Targeted therapy has radically altered the way metastatic renal cancer is treated. Six drugs are now licensed in this setting, with several other agents under evaluation. Sunitinib is currently the most widely used in the first line setting with impressive efficacy and an established toxicity profile. However, as further randomised studies report and as newer drugs become available this may change. In this review, we address our current understanding of targeted therapy in renal cancer. We also discuss areas in which our knowledge is incomplete, including the identification of correlative biomarkers and mechanisms of drug resistance. Finally, we will describe the major areas of clinical research that will report over the next few years. British Journal of Cancer (2011) 104, 741-745. doi:10.1038/sj.bjc.6606061 www.bjcancer.com Published online 25 January 2011 (C) 2011 Cancer Research UK
引用
收藏
页码：741 / 745
页数：5
相关论文
共 38 条
  • [1] Modes of resistance to anti-angiogenic therapy
    Bergers, Gabriele
    Hanahan, Douglas
    [J]. NATURE REVIEWS CANCER, 2008, 8 (08) : 592 - 603
  • [2] Bhargava P, 2009, J CLIN ONCOL, V27
  • [3] Cenni E, 2005, ANTICANCER RES, V25, P1109
  • [4] Choueiri TK, 2008, J CLIN ONCOL, V26, P127, DOI 10.1200/JCO.2007.13.3223
  • [5] ESCUDIER B, 2010, J CLIN ONCOL S, V28, pS7
  • [6] Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
    Escudier, Bernard
    Pluzanska, Anna
    Koralewski, Piotr
    Ravaud, Alain
    Bracarda, Sergio
    Szczylik, Cezary
    Chevreau, Christine
    Filipek, Marek
    Melichar, Bohuslav
    Bajetta, Emilio
    Gorbunova, Vera
    Bay, Jacques-Olivier
    Bodrogi, Istvan
    Jagiello-Gruszfeld, Agnieszka
    Moore, Nicola
    [J]. LANCET, 2007, 370 (9605) : 2103 - 2111
  • [7] Sorafenib in advanced clear-cell renal-cell carcinoma
    Escudier, Bernard
    Eisen, Tim
    Stadler, Walter M.
    Szczylik, Cezary
    Oudard, Stephane
    Siebels, Michael
    Negrier, Sylvie
    Chevreau, Christine
    Solska, Ewa
    Desai, Apurva A.
    Rolland, Frederic
    Demkow, Tomasz
    Hutson, Thomas E.
    Gore, Martin
    Freeman, Scott
    Schwartz, Brian
    Shan, Minghua
    Simantov, Ronit
    Bukowski, Ronald M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) : 125 - 134
  • [8] Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
    Escudier, Bernard
    Roigas, Jan
    Gillessen, Silke
    Harmenberg, Ulrika
    Srinivas, Sandhya
    Mulder, Sasja F.
    Fountzilas, George
    Peschel, Christian
    Flodgren, Per
    Maneval, Edna Chow
    Chen, Isan
    Vogelzang, Nicholas J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (25) : 4068 - 4075
  • [9] Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma
    Escudier, Bernard
    Szczylik, Cezary
    Hutson, Thomas E.
    Demkow, Tomasz
    Staehler, Michael
    Rolland, Frederic
    Negrier, Sylvie
    Laferriere, Nicole
    Scheuring, Urban J.
    Cella, David
    Shah, Sonalee
    Bukowski, Ronald M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (08) : 1280 - 1289
  • [10] Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer
    Flanigan, RC
    Salmon, SE
    Blumenstein, BA
    Bearman, SI
    Roy, V
    McGrath, PC
    Caton, JR
    Munshi, N
    Crawford, ED
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (23) : 1655 - 1659
1234